The future of obesity: New drugs versus lifestyle interventions

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 263-267

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diet; Drug therapy; Lifestyle; Obesity; Weight loss

Indexed keywords

ANTIOBESITY AGENT; GLUCOSE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BEHAVIOR THERAPY; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; EXERCISE; GLUCOSE METABOLISM; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MAINTENANCE THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; RISK REDUCTION; TREATMENT OUTCOME; WEIGHT REDUCTION; DRUG DESIGN; KINESIOTHERAPY; LIFESTYLE;

ANTI-OBESITY AGENTS; DRUG DESIGN; EXERCISE THERAPY; HUMANS; LIFE STYLE; OBESITY;

EID: 40949165265     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.263     Document Type: Editorial

References (20)

1. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209
2. Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 2006;27:750-61
3. Scheen AJ. Integrated approach to treatment and prevention. In: Pharmacotherapy of Obesity. Options and Alternatives. Hofbauer KG, Keller U, Boss O, editors. Boca Raton, FL: CRC Press; 2004. p. 449-63
4. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9
5. Snow V, Barry P, Fitterman N, et al. For the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;142:525-31
6. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84
7. Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 2007;3:123-33
8. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-67
9. Bray GA. Medical therapy for obesity - current status and future hopes. Med Clin North Am 2007;91:1225-53
10. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
11. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9
12. American Dietetic Association. Position of the American Dietetic Association: integration of medical nutrition therapy and pharmacotherapy. J Am Diet Assoc 2003;103:1363-70
13. Wadden TA, Berkovitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20
14. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-13
15. Scheen AJ. Cannabinoid- 1 receptor antagonists in type-2 diabetes. Best Pract.Res Clin Endocrinol Metab 2007;21:535-53
16. Van Gaal LF, Pi-Sunyer X, Després JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the RIO program. Diabetes Care 2008;31 (Suppl 2):S229-40
17. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther, 2006;4:871-95
18. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
19. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005;7(Suppl L):L44-8
20. Sjöström L, Narbro, K, Sjöström CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52